Last reviewed · How we verify
Osiris Phleum pratense
Osiris Phleum pratense is a Biologic drug developed by ALK-Abelló A/S. It is currently in Phase 2 development.
At a glance
| Generic name | Osiris Phleum pratense |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Osiris Phleum pratense CI brief — competitive landscape report
- Osiris Phleum pratense updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI
Frequently asked questions about Osiris Phleum pratense
What is Osiris Phleum pratense?
Osiris Phleum pratense is a Biologic drug developed by ALK-Abelló A/S.
Who makes Osiris Phleum pratense?
Osiris Phleum pratense is developed by ALK-Abelló A/S (see full ALK-Abelló A/S pipeline at /company/alk-abell-a-s).
What development phase is Osiris Phleum pratense in?
Osiris Phleum pratense is in Phase 2.
Related
- Manufacturer: ALK-Abelló A/S — full pipeline
- Compare: Osiris Phleum pratense vs similar drugs
- Pricing: Osiris Phleum pratense cost, discount & access